Averna Therapeutics is a biotechnology company developing Ribonucleic acid (RNA) and lipid nanoparticle (LNP)-based genomic medicines to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions.
Our proprietary technology is based on a natural system and inserts therapeutic genetic instructions into “safe harbor” sites in the genome – genomic regions that allow stable gene integration without disrupting normal cell function.
Because our medicines are encoded in RNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent.
Follow us on LinkedIn and stay in touch as we seek to advance develop RNA/LNP-based genomic medicines that deliver meaningful solutions for patients!
Company Details
- Employees
- 48
- Address
- Manager Jobs
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://avernatx.com/
- Keywords
- Seaport Therapeutics.
Averna Therapeutics Questions
Averna Therapeutics's website is https://avernatx.com/
Averna Therapeutics's LinkedIn profile is https://www.linkedin.com/company/avernatx
Averna Therapeutics has
48 employees.
View email and phone details for 48
employees at Averna Therapeutics.
Averna Therapeutics's industry is
Biotechnology Research
Averna Therapeutics's top competitors are
Seaport Therapeutics,
Evolutionaryscale,
Xaira Therapeutics,
Endogenex,
Formation Bio,
Orna Therapeutics,
Augustine Therapeutics,
Flamingo Therapeutics,
Alumis,
Venostent, Inc..
Averna Therapeutics's categories are Biotechnology Research
